Arash Rezazadeh Kalebasty, MD

Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.

Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate or enzalutamide.